Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW
by Zacks Equity Research
Abbott (ABT) is is leaving no stone unturned to drive its Structural Heart business.
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus
by Urmimala Biswas
According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
by Zacks Equity Research
Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Abbott to Strengthen Vascular Care Arm With Surmodics Deal
by Zacks Equity Research
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Cardiovascular Systems Portfolio Solid, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.
Abbott's FreeStyle LibreLink App Now Available in Europe
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.
Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.
Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.
HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)
by Zacks Equity Research
HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.
MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN
by Zacks Equity Research
The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.
Boston Scientific's (BSX) Millipede Deal Aids MR Business
by Zacks Equity Research
Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.
Markets Keep Gaining Amid Strong Corporate Earnings
by Zacks Equity Research
Markets Keep Gaining Amid Strong Corporate Earnings
Plethora of Q4 Earnings Amid New Market Highs
by Mark Vickery
From GE and Comcast to United Technologies and General Dynamics, the latest round of Q4 earnings results is accounted for.
Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance
by Zacks Equity Research
Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.
Abbott (ABT) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abbott (ABT) rides high on new product approvals and launches in Q4.
This Week's Amazing Earnings Charts
by Tracey Ryniec
These 5 companies have consistently beat the earnings estimate. Will they do it again?
Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.
Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre
by Zacks Equity Research
Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.